Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer

By Lidgren Mathias   Wilking Nils   Jonsson Bengt   Rehnberg Clas  

Acta Oncologica, Vol. 47, Iss. 6, 2008-08 ,pp. : 1018-1028

Informa Healthcare

Access to resources Recommend Favorite

Preoperative Therapy Using Trastuzumab and Weekly Paclitaxel in a Stage III B Inoperable Locally Advanced HER2-Positive Breast Cancer with Complete Pathologic Response

By Rai Yoshiaki   Sagara Yoshiatsu   Ooi Yasuyo   Yasuaki   Sagara Yoshiaki   Baba Shinichi   Tamada Syugo   Matsuyama Yoshito   Ando Mitsutake  

Japanese Journal of Cancer and Chemotherapy, Vol. 36, Iss. 3, 2009-03 ,pp. : 471-473

Sunmedia

Access to resources Recommend Favorite

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

By Aogi Kenjiro   Saeki Toshiaki   Nakamura Seigo   Kashiwaba Masahiro   Sato Nobuaki   Masuda Norikazu   Rai Yoshiaki   Ohno Shinji   Kuroi Katsumasa   Nishimura Reiki   Miyakoda Keiko   Akiyama Futoshi   Kurosumi Masafumi   Ikeda Tadashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 598-606

Springer Publishing Company

Access to resources Recommend Favorite